(Q36586891)

15 August 2017

1 reference

title

Immunosuppressive preconditioning or induction regimens : evidence to date (English)

1 reference

15 August 2017

3

Ron Shapiro

1 reference

15 August 2017

Henkie P Tan

1

1 reference

15 August 2017

Marc C Smaldone

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

66

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1535-1545

1 reference

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients

15 August 2017

cites work

1 reference

12 December 2020

Pancreatic transplantation at the University of Pittsburgh

1 reference

12 December 2020

Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?

1 reference

12 December 2020

Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation

1 reference

12 December 2020

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation

1 reference

12 December 2020

A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation

1 reference

12 December 2020

Basiliximab: a review of its use as induction therapy in renal transplantation

1 reference

12 December 2020

Monoclonal antibodies in renal transplantation: old and new

1 reference

12 December 2020

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

1 reference

12 December 2020

Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy

1 reference

12 December 2020

Reversal of acute cellular rejection after renal transplantation with Campath-1H.

1 reference

12 December 2020

Multivariate analyses of antibody induction therapies.

1 reference

12 December 2020

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

1 reference

12 December 2020

Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1

1 reference

12 December 2020

Transplantation tolerance from a historical perspective

1 reference

12 December 2020

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection

1 reference

12 December 2020

Overcoming a positive crossmatch in living-donor kidney transplantation.

1 reference

12 December 2020

Rituximab as treatment for refractory kidney transplant rejection

1 reference

12 December 2020

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

1 reference

12 December 2020

Lymphomas after solid organ transplantation: a collaborative transplant study report

1 reference

12 December 2020

Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation

1 reference

12 December 2020

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

1 reference

12 December 2020

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation.

1 reference

12 December 2020

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance

1 reference

12 December 2020

Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation

1 reference

12 December 2020

Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation

1 reference

12 December 2020

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

1 reference

12 December 2020

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

12 December 2020

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

1 reference

12 December 2020

Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

1 reference

12 December 2020

In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts

1 reference

12 December 2020

Specificity of monoclonal antibody Campath-1

1 reference

12 December 2020

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

1 reference

12 December 2020

Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.

1 reference

12 December 2020

Comparison of antilymphocyte globulin and continuous i.v. cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study

1 reference

12 December 2020

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

1 reference

12 December 2020

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

12 December 2020

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

1 reference

12 December 2020

A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Stu

1 reference

12 December 2020

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

1 reference

12 December 2020

Antilymphocyte antibodies, renal transplantation, and meta-analysis

1 reference

12 December 2020

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

12 December 2020

Preliminary results of a prospective randomized clinical trial comparing cyclosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation

1 reference

12 December 2020

Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1

1 reference

12 December 2020

Systemic chimerism in human female recipients of male livers

1 reference

12 December 2020

A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.

1 reference

12 December 2020

Adhesion molecules and activation markers in acute rejection of human renal allografts

1 reference

12 December 2020

Immunosuppressive drugs for kidney transplantation.

1 reference

12 December 2020

A randomized clinical trial of induction therapy with OKT3 in kidney transplantation

1 reference

12 December 2020

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

1 reference

12 December 2020

Immunosuppression and tolerance for clinical organ allografts

1 reference

12 December 2020

Campath-1H use in pediatric renal transplantation

1 reference

12 December 2020

A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function

1 reference

12 December 2020

Expression of ICAM-1 and LFA-1 molecules in relation to renal allograft rejection in rats

1 reference

12 December 2020

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

12 December 2020

The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.

1 reference

12 December 2020

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

1 reference

12 December 2020

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

1 reference

12 December 2020

Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation

1 reference

12 December 2020

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression

1 reference

12 December 2020

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

1 reference

12 December 2020

Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin)

1 reference

12 December 2020

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

1 reference

12 December 2020

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

12 December 2020

Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group

1 reference

12 December 2020

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

1 reference

12 December 2020

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

1 reference

12 December 2020

Antigen localization and migration in immunity and tolerance

1 reference

12 December 2020

Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury

1 reference

12 December 2020

The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group

1 reference

12 December 2020

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

1 reference

12 December 2020

The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation--a single-center, prospective, randomized study

1 reference

12 December 2020

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

1 reference

12 December 2020

Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

1 reference

12 December 2020

Campath-1H in renal transplantation: The University of Wisconsin experience.

1 reference

12 December 2020

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

1 reference

12 December 2020

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy

1 reference

12 December 2020

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

1 reference

12 December 2020

Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study

1 reference

12 December 2020

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

1 reference

12 December 2020

Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.

1 reference

12 December 2020

CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

1 reference

12 December 2020

Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning

1 reference

12 December 2020

Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation

1 reference

12 December 2020

The impact of Campath 1H induction in adult liver allotransplantation

1 reference

12 December 2020

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

12 December 2020

10.2165/00003495-200666120-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1049807588

0 references

1 reference